Medline’s $6.3bn IPO becomes 2025’s biggest and signals a reopening IPO windowOpening Today’s story is a big one for markets: medical supplies giant Medline has priced an upsized IPO at $29 and raised about $6.26bn–$6.3bn, set to trade on Nasdaq as $MDLN. It’s the biggest IPO of 2025 and one of the largest US listings in years, with proceeds aimed largely at reducing debt. What happened and why it matters Medline is a massive medical-surgical products supplier with deep distribution and logistics reach across healthcare. The IPO size and pricing suggest investors are willing to fund large, private equity-backed exits again, even after periods of volatility. That matters because a reopening IPO window can change sector leadership: it boosts “toll collectors” in capital markets, helps private equity monetise assets, and creates a new public benchmark for healthcare supply-chain valuations. Winners (3 categories)Capital markets “toll collectors” Why: Big IPOs mean underwriting fees, trading volumes, and listing revenue. A healthier IPO pipeline tends to lift sentiment across brokers, exchanges, and market infrastructure.Names: $NDAQ $ICE $GS $MSAlternative asset managers and private equity platforms Why: A successful, blockbuster PE-backed listing is a proof point that exits are viable again. That supports fee narratives (realisation cycles, distributions, fundraising confidence).Names: $BX $CG $KKR $APO $ARES Healthcare supplies and medtech “volume ecosystem” Why: When a major distributor/operator is well-funded and expanding, it can reinforce demand signals across the broader medical consumables and device supply chain. Also, strong IPO demand can lift valuation comps for adjacent healthcare suppliers.Names: $BDX $STE $MDT $ABTLosers (3 categories)Direct medical distribution and supply-chain rivals Why: A newly public, well-capitalised Medline can invest more aggressively in pricing, logistics, and customer capture. That can pressure margins and growth expectations for competing distributors and supply players.Names: $MCK $CAH $OMI $HSICHospital operators exposed to supply-cost negotiation risk Why: If distributors gain leverage (or if supply chains tighten), hospitals can see pressure on operating costs and contracting dynamics. Even small changes in supply costs can matter when margins are thin.Names: $HCA $THC $UHSDefensive “bond-proxy” equities in a risk-on tape Why: When the market mood shifts toward risk-taking (IPO window reopening, big deals clearing), defensives can lag as flows rotate toward growth/cyclicals and away from yield stability.Names: $DUK $SO $AEP#StockMarket #Trading #Investing #DayTrading #SwingTrading #IPO #Nasdaq #Healthcare #MedTech #PrivateEquity #CapitalMarkets #Earnings #Stocks

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.